| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
87,420,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Centessa Pharmaceuticals is a pharmaceutical company that develops and delivers life-altering and life-enhancing medicines to patients. Co.'s product pipeline includes: Lixivaptan, a vasopressin V2 receptor small molecule inhibitor; SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody for the treatment of cutaneous squamous cell carcinoma and for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin for the treatment of alpha-1-antitrypsin deficiency.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
10,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$46,284 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
51,160 |
55,427 |
107,411 |
368,796 |
| Total Sell Value |
$607,960 |
$642,534 |
$943,036 |
$2,119,530 |
| Total People Sold |
1 |
2 |
4 |
10 |
| Total Sell Transactions |
1 |
2 |
5 |
35 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Grainger David J |
Chief Innovation OfficerOffice |
• – – |
2021-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
813,756 |
|
- |
|
| Hussain Iqbal J |
General Counsel |
• – – |
2021-06-02 |
4 |
B |
$20.00 |
$110,000 |
I/I |
5,500 |
5,500 |
1.99 |
- |
|
| Hussain Iqbal J |
General Counsel |
• – – |
2021-06-02 |
4 |
B |
$20.00 |
$60,000 |
D/D |
3,000 |
3,000 |
2.74 |
- |
|
| Medicxi Growth I Gp Ltd |
10% Owner |
– – • |
2021-06-02 |
4 |
B |
$20.00 |
$12,000,000 |
I/I |
600,000 |
88,887 |
1.5 |
- |
|
| Medicxi Growth I Gp Ltd |
10% Owner |
– – • |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
I/I |
1,931,818 |
74,964 |
|
- |
|
| Thorell Marella |
Chief Accounting Officer |
• – – |
2021-06-02 |
4 |
B |
$20.00 |
$20,000 |
D/D |
1,000 |
1,000 |
2.74 |
- |
|
| Weinhoff Gregory M |
Chief Financial Officer |
• – – |
2021-06-02 |
4 |
B |
$20.00 |
$200,000 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
| Chao David M |
Chief Administrative Officer |
• – – |
2021-06-02 |
4 |
B |
$20.00 |
$10,000 |
D/D |
500 |
500 |
2.74 |
- |
|
| De Rubertis Francesco |
Director |
– • – |
2021-06-02 |
4 |
B |
$20.00 |
$12,000,000 |
I/I |
600,000 |
88,887 |
2.1 |
- |
|
| De Rubertis Francesco |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
I/I |
1,931,818 |
74,964 |
|
- |
|
| Templeman Thomas |
Chief Technology Officer |
• – – |
2021-06-02 |
4 |
B |
$20.00 |
$5,000 |
D/D |
250 |
250 |
2.74 |
- |
|
| Goyal Arjun |
Director |
– • – |
2021-06-02 |
4 |
B |
$20.00 |
$15,000,000 |
I/I |
750,000 |
106,159 |
2.1 |
- |
|
| Goyal Arjun |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,181,818 |
85,909 |
|
- |
|
| Bush Tia L |
Chief Quality Officer |
• – – |
2021-06-02 |
4 |
B |
$20.00 |
$60,000 |
I/I |
3,000 |
3,000 |
1.99 |
- |
|
| General Atlantic Um B.v. |
10% Owner |
– – • |
2021-06-02 |
4 |
B |
$20.00 |
$30,000,000 |
D/D |
1,500,000 |
9,681,818 |
2.45 |
- |
|
| Medicxi Secondary I Gp Ltd. |
10% Owner |
– – • |
2021-05-27 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
15,392,074 |
|
- |
|
| Index Venture Life Associates Vi Ltd |
10% Owner |
– – • |
2021-05-27 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
9,961,789 |
|
- |
|
| Yver Antoine |
Chief Medical Officer |
• – – |
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
833,897 |
833,897 |
|
- |
|
| Medicxi Secondary I Lp |
10% Owner |
– – • |
2021-05-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
15,392,074 |
|
- |
|
| De Rubertis Francesco |
Director |
– • – |
2021-05-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
15,392,074 |
|
- |
|
| Yucca (jersey) Slp |
10% Owner |
– – • |
2021-05-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,961,789 |
|
- |
|
| Kantoff Aaron |
Director |
– • – |
2021-05-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
50,000 |
|
- |
|
147 Records found
|
|
Page 6 of 6 |
|
|
